Objective: Blunted tachycardia during hypotension is a characteristic feature of patients with autonomic failure, but the range has not been defined. This study reports the range of orthostatic heart rate (HR) changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Methods: Patients evaluated at sites of the U.S. Autonomic Consortium (NCT01799915) underwent standardized autonomic function tests and full neurological evaluation. Results: We identified 402 patients with orthostatic hypotension (OH) who had normal sinus rhythm. Of these, 378 had impaired sympathetic activation (ie, neurogenic OH) and based on their neurological examination were diagnosed with Parkinson disease, dementia with Lewy bodies, pure autonomic failure, or multiple system atrophy. The remaining 24 patients had preserved sympathetic activation and their OH was classified as nonneurogenic, due to volume depletion, anemia, or polypharmacy. Patients with neurogenic OH had twice the fall in systolic blood pressure (SBP; 244 6 25 vs 221 6 14 mmHg [mean 6 standard deviation], p < 0.0001) but only one-third of the increase in HR of those with nonneurogenic OH (8 6 8 vs 25 6 11 beats per minute [bpm], p < 0.0001). A DHR/DSBP ratio of 0.492 bpm/mmHg had excellent sensitivity (91.3%) and specificity (88.4%) to distinguish between patients with neurogenic from nonneurogenic OH (area under the curve 5 0.96, p < 0.0001). Within patients with neurogenic OH, HR increased more in those with multiple system atrophy (p 5 0.0003), but there was considerable overlap with patients with Lewy body disorders. Interpretation: A blunted HR increase during hypotension suggests a neurogenic cause. A DHR/DSBP ratio < 0.5 bpm/mmHg is diagnostic of neurogenic OH. ANN NEUROL 2018;83:522-531 O rthostatic hypotension (OH) is defined as a sustained fall in systolic blood pressure (SBP) of at least 20mmHg or diastolic blood pressure (DBP) of 10mmHg or more after standing for 3 minutes.
increase upon standing. 3, 4 Patients with neurogenic OH usually have little or no increase in HR in the upright position, whereas patients with nonneurogenic OH due to, for example, intravascular volume depletion or physical deconditioning, typically have marked tachycardia. Despite its importance in the differential diagnosis of OH, the range of orthostatic HR changes has not been systematically analyzed and normative data are not available. Neither the first nor the second OH consensus criteria defined HR ranges. 1, 5 A recent consensus panel
proposed an increase in HR of <15 beats per minute (bpm) to support the diagnosis of neurogenic OH, but this proposed range was based on experts' clinical experience rather than scientific evidence. 6 Knowing the actual range of HR changes in patients with carefully diagnosed autonomic failure should be helpful for clinicians. Moreover, it is not known whether orthostatic HR changes differ in patients with lesions of the central or peripheral autonomic nervous system. Distinguishing both types of autonomic involvement (central vs peripheral) is important, as these two groups differ in response to treatment, comorbidities, and prognosis.
Because tachycardia when standing is largely dependent on sympathetic innervation of the sinus node, 7 we
hypothesized that the orthostatic HR responses will be more impaired in patients with peripheral sympathetic cardiac denervation (ie, Parkinson disease [PD] , dementia with Lewy bodies [DLB] , and pure autonomic failure [PAF]) compared to those with selective central autonomic lesions (ie, multiple system atrophy [MSA] ), in whom the sympathetic postganglionic innervation of the heart is typically spared. 8, 9 To test this hypothesis, we describe the range of orthostatic HR changes in a large cohort of patients with carefully characterized autonomic failure and OH due to synucleinopathies. [10] [11] [12] As a comparison group, we also studied a group of patients with nonneurogenic OH. These findings will help clinicians diagnose neurogenic OH.
Patients and Methods

Subjects
Between September 2011 and January 2016, we prospectively studied 423 consecutive adult patients referred for autonomic evaluation at sites within the U.S. Autonomic Disorders Consortium (NCT01799915). The criteria to diagnose OH included a sustained fall in SBP of at least 20mmHg or DBP of 10mmHg or more after standing for 3 minutes. 1 Patients with diabetes mellitus, lupus, congestive heart failure, isolated vasovagal syncope, autoimmune etiologies, infectious diseases, 13 or amyloidosis were excluded from this study. Patients with OH that had no overshoot in BP after the Valsalva strain (ie, phase IV of the Valsalva maneuver) were categorized as having neurogenic OH on account of impaired baroreflex-mediated sympathetic activation. 14, 15 Patients who met criteria for OH who had a BP overshoot following release of the Valsalva strain and an identifiable cause for their OH (eg, anemia, polypharmacy, varicose veins) were diagnosed as having nonneurogenic OH on the basis of their intact baroreflex-mediated sympathetic activation.
Categorizing the Lesions of Patients with Neurogenic OH
Based on the known neuropathology of neurodegenerative synucleinopathies (Fig 1) , 16, 17 patients with neurogenic OH were classified clinically as having central or peripheral forms of autonomic sympathetic failure according to their neurological examination and diagnostic workup (eg, brain magnetic resonance imaging). [18] [19] [20] As depicted in Figure 1B , central autonomic involvement included patients diagnosed clinically with probable or possible MSA based on current consensus criteria. 18, 21 Peripheral autonomic involvement included patients with PAF and no evidence of central nervous system (CNS) involvement (ie, no rapid eye movement [REM] sleep behavior disorder, olfactory dysfunction, or subtle motor signs) 22 as well as those fulfilling current clinical consensus criteria for a known Lewy body CNS disorder (PD, DLB). 22, 23 Patients diagnosed with neurogenic OH who also had REM sleep behavior disorder, anosmia, and/or subtle motor signs were categorized as prodromal PD/DLB or prodromal MSA, because longitudinal studies have shown that they are already affected by an underlying CNS neurodegenerative disorder. 22, 24, 25 Because it was unclear at the time of testing whether these patients would ultimately transition into PD/DLB or MSA, they were excluded from the subgroup analysis to understand the impact of disease-specific lesions.
Sites
Recruiting sites were part of the U.S. Autonomic Disorders Consortium and supported by the National Institutes for Health (NIH) Rare Disease Clinical Research Network (RDCRN). 22 All sites had expertise in autonomic neurology. 
Protocol
Participants were free of caffeine, alcohol, and nicotine from the previous evening. Subjects underwent a comprehensive medical history 26 and a standardized battery of autonomic function tests, in a quiet, temperature-controlled room. An intravenous forearm catheter was inserted into the antecubital vein, and subjects were transferred to the tilt-table for instrumentation to complete a 10-minute head-up tilt and collection of supine and 60 8 head-up tilt plasma norepinephrine (NE) samples. Continuous electrocardiographic monitoring included RR interval recording from 3 precordial electrodes. Beat-to beat BP was measured with finger plethysmography with the hand supported at heart level. Intermittent BP was also measured at 1-minute intervals with a validated automated cuff sphygmomanometer over the brachial artery. All signals were acquired and digitized and sampled at a minimum rate of 500Hz. Subjects in nonsinus rhythm were excluded from further analysis.
As a measure of parasympathetic function, subjects were coached to breathe at 6 cycles per minute, and respiratory sinus arrhythmia during deep paced breathing was calculated from the average of the 3 longest RR intervals during expiration divided by the average of the 3 shortest RR intervals during inspiration (ie, expiratory:inspiratory [E:I] ratio).
14 A 300-second segment of spontaneous breathing in the supine position was selected and processed to detect RR intervals from the electrocardiogram. Beat-to-beat HR variability (HRV) in the time and frequency domains was measured following standards outlined in the manual of operations. 27 Venous blood was sampled through the indwelling catheter after at least 15 minutes supine to assay plasma NE levels by high-performance liquid chromatography. 22 Subjects then performed a standardized Valsalva maneuver, 15 maintaining an expiratory pressure of >30mmHg for at least 10 seconds. If BP was not higher than baseline within 10 seconds after release of the Valsalva strain (ie, phase IV), the overshoot in BP was considered absent, indicative of sympathetic (autonomic) failure. Cases with partial recovery of the BP in phase IV, suggesting some preservation of baroreflexmediated sympathetic activation, were not included. Pressure recovery time was measured as the time (in seconds) taken for Only those in normal sinus rhythm in whom the heart rate responses could be clearly attributed to extrinsic autonomic innervation were included in the subsequent analysis. Patients were classified as having neurogenic or nonneurogenic orthostatic hypotension (OH) and both groups were compared (I). (B) Based on their neurological examination, cases of neurogenic OH were diagnosed with either probable or possible multiple system atrophy (MSA), and thus classified as having central autonomic failure (due to neuronal loss in the brainstem vasomotor nuclei and intermediolateral columns of the spinal cord, 49 but intact peripheral postganglionic sympathetic neurons innervating the heart), 50 or Parkinson disease (PD), dementia with Lewy bodies (DLB), or pure autonomic failure (PAF). 22, 49, 51 The latter group was classified as having peripheral lesions, as a result of predominant involvement of peripheral postganglionic sympathetic neurons. 23 Parasympathetic activity (not shown) was equally affected in patients with central and peripheral autonomic failure. The remaining patients who had autonomic failure with central nervous system (CNS) signs, but did not meet diagnostic criteria for a defined CNS synucleinopathy, were classified as having prodromal disease (see text for details). The impact of central versus peripheral autonomic failure was compared (A II). AV 5 atrioventricular node; IML 5 intermediolateral nucleus; RVLM 5 rostral ventrolateral medulla; SN 5 sinoatrial node.
the systolic BP to return to baseline (prestrain) values following release of the Valsalva strain. 15, 28 Subjects were then tilted upright to an angle of 60 8 and instructed to remain immobile. After 10 minutes upright, a second set of blood samples for plasma catecholamine measurements were acquired. Patients also underwent a complete blood count to screen for anemia and metabolic panel to screen for dehydration or electrolyte imbalances.
The procedure for defining the orthostatic HR response was standardized across all sites; average HR over the 5 minutes of supine rest during spontaneous breathing was used to define baseline (pretilt) resting supine value. Orthostatic HR responses were calculated as the difference between HR at baseline and at 3 minutes of passive upright tilt. Cardiac baroreflex gain was assessed with 2 methods: (1) by calculating the slope of the regression line comparing changes in systolic BP against RR intervals during baseline and phases I, II (lowest BP and shortest RR interval during the straining phase), and IV of the Valsalva maneuver and expressed as ms/mmHg, as previously described 29 ; and (2) by dividing the change (D) in HR by the fall (D) in SBP at the 3-minute mark upright and expressed as bpm/mmHg (DHR/DSBP ratio).
Statistical Analysis
Data were first tested for normality using the Shapiro-Wilk and Kolmogorov-Smirnov tests. Parametric and nonparametric evaluations were used as appropriate. Supine hypertension was defined as BP > 140/90mmHg in the horizontal position. 30 Linear regression analysis and Pearson correlation coefficients were used to assess the relationship between RR intervals and hemodynamic parameters. Differences between groups were compared using 2-way analysis of variance with multiple comparisons or Kruskal-Wallis test. To account for multiple comparison errors, we applied a Bonferroni correction. Patients were stratified a priori as having autonomic failure due to lesion in the central or peripheral autonomic nervous system. The impact of central versus peripheral neurodegenerative lesions on HR responses was examined with analysis of covariance (ANCOVA) and post hoc multiple comparisons.
We calculated the sensitivity and the specificity of the orthostatic HR increase to distinguish between neurogenic and nonneurogenic OH, and between neurogenic OH of central and of peripheral origin using receiver operating characteristic curves assuming nonparametric conditions. 31 With a similar method, we also calculated the sensitivity and specificity of the DHR/DSBP ratio, a marker of cardiac baroreflex gain, to distinguish between neurogenic and nonneurogenic OH, and between central and peripheral neurogenic OH. Differences between groups were further assessed with ANCOVA using age as a covariant. Data were analyzed with SPSS 19.0 (SPSS, Chicago, IL) and Prism (GraphPad Software, La Jolla, CA) and expressed in mean 6 standard deviation (SD) unless otherwise specified. Significance was set at p < 0.05.
Results
Subject Characteristics
We identified 444 patients who met criteria for OH (see Fig 1A) . Of these, 42 patients (9.4%) were excluded because they were not in normal sinus rhythm at the time of testing (remaining cohort n 5 402). This subgroup of excluded patients with nonsinus rhythm was similar to those with normal sinus rhythm in age (p 5 0.247), distribution of diagnosis, and fall in BP after 3 minutes of head-up tilt (SBP p 5 0.895, DBP p 5 0.478).
As shown in the Table, 378 cases had sympathetic and parasympathetic autonomic failure and were diagnosed as having neurogenic OH. The remaining 24 cases had preserved sympathetic and parasympathetic reflexes and were diagnosed with nonneurogenic OH. The age of the neurogenic OH cohort was 72 6 10 years (mean 6 SD; range 5 44-98 years), similar to the nonneurogenic cohort. In the supine position, BP was higher in the neurogenic than in the nonneurogenic cohort. The prevalence of supine hypertension in the neurogenic OH cohort was 71% (n 5 269/378).
Autonomic Features
As also shown in the Table, resting HR was almost the same in the neurogenic and nonneurogenic groups. All patients with neurogenic OH had evidence of baroreflex impairment, with a profound decrease in SBP during phase II of the Valsalva strain (254 6 29mmHg) accompanied by only a small shortening of RR intervals (2116 6 121 milliseconds). Pressure recovery time was prolonged in all cases, confirming autonomic failure (see Table) . 32, 33 The average baroreflex "cardiac gain" calculated with regression analysis using data from all phases of the Valsalva maneuver was lower in patients with neurogenic versus nonneurogenic OH (p 5 0.0017), and lower than in age-matched healthy subjects. 34 As shown in Figure 2 , the normal increase in the plasma concentration of NE in the upright position was reduced in patients with neurogenic OH, confirming impaired baroreflex-mediated sympathetic activation (153 6 78% increase in NE, D%). In contrast, plasma NE concentration more than doubled with upright tilt in patients with nonneurogenic OH (1115 6 67 D%, p 5 0.015), confirming their fully functional baroreflexmediated sympathetic activation.
Orthostatic HR and BP Changes After 3 minutes of upright tilt, the BP fall was significantly more pronounced in the cohort with neurogenic OH (SBP: 243 6 25 vs nonneurogenic 221 6 14 mmHg, p < 0.0001). Despite the marked fall in BP in the neurogenic OH group, the HR increase was much lower than in the nonneurogenic group (18 6 8 bpm vs nonneurogenic 1 25 6 11 bpm, p < 0.0001). In patients with neurogenic OH, the orthostatic HR response was The simple bedside measure of cardiac baroreflex gain calculated as the ratio of HR to SBP changes at 3 minutes of tilt (DHR/DSBP ratio) was significantly reduced in patients with neurogenic versus nonneurogenic OH (0.227 6 0.256 vs 1.347 6 0.794, p < 0.0001; Fig 3C) . This simple measurement of baroreflex function correlated (R 2 5 0.1101; p 5 0.0001) with the more complex baroreflex sensitivity index calculated using the BP and HR changes during the Valsalva maneuver. The orthostatic HR increase alone had poor discriminatory capacity to distinguish between neurogenic and nonneurogenic OH in individual patients. In this regard, an HR increase of <17 bpm had only moderate sensitivity (79%) and specificity (87%; area under the curve [AUC] 5 0.89, 95% confidence interval [CI] 5 0.83-0.95, p < 0.0001; see Fig 3B) . The DHR/ DSBP ratio had a considerably better sensitivity and specificity to discriminate between patients with neurogenic and nonneurogenic OH than the HR increase alone. A DHR/DSBP ratio of 0.492 bpm/mmHg yielded the best combined sensitivity (91.3%) and specificity (88.4%) to distinguish between neurogenic and nonneurogenic OH (AUC 5 0.96, 95% CI 5 0.95-0.99, p < 0.0001; see Fig 3D) .
Impact of Central versus Peripheral Autonomic Failure
The cohort included 96 patients with central autonomic failure (MSA) and 128 patients with peripheral autonomic failure (PAF 5 13, DLB 5 19, PD 5 96; see Fig 1  and Table) . The 13 patients with PAF included in the peripheral category had symptomatic neurogenic OH and no clinical signs of CNS deficits (no REM sleep behavior disorder, normal olfaction, and no subtle signs of motor impairment). 22 One hundred fifty-one patients with neurogenic OH also had anosmia or REM sleep behavior disorder and were thus classified as probable prodromal PD/DLB or MSA. 22 Because these "prodromal" patients did not fit current diagnostic consensus criteria and it was unclear at the time of testing whether they would evolve into central (MSA) or peripheral (PD/DLB) forms of autonomic failure, they were excluded from the subgroup analysis to understand the impact of disease-specific lesions on HR.
The Table shows Among the patients with neurogenic OH, as shown in Figure 2 , supine plasma NE levels were highest in patients with central autonomic failure (370 6 284pg/ ml), reflecting preserved postganglionic sympathetic neurons. Resting HR, HR in the upright tilt position, and the orthostatic HR change were higher in patients with central autonomic failure (see Table and Fig 3) .
HR increased significantly more in patients with central than in those with peripheral autonomic failure. When age was used as a covariant, the orthostatic HR response remained significantly higher in patients with MSA compared to those with Lewy body disorders (ANCOVA, p 5 0.023). Because of overlap, however, the HR increase had no discriminatory capacity to distinguish between central and peripheral neurogenic OH in individual patients. An HR increase of <10 bpm had poor sensitivity (52%) and specificity (65%) to do so (AUC 5 0.61, 95% CI 5 0.533-0.69, p 5 0.0084).
The DHR/DSBP ratio was not different between the central and peripheral groups. Similarly, the baroreflex gain index based on hemodynamic changes during the Valsalva maneuver also failed to show differences in patients with central versus peripheral autonomic failure (see Table) .
Discussion
Our results show that neurogenic OH can be diagnosed accurately based on the reduced increase in HR in relation to the fall in SBP. A DHR/DSBP ratio after 3 minutes in the standing position lower than 0.5 bpm/ mmHg can discriminate patients with neurogenic from those with nonneurogenic OH with excellent sensitivity (91.3%) and specificity (88.4%).
In contrast, the distinction between central and peripheral causes of neurogenic OH is more challenging. HR rises significantly less in patients with Lewy body disorders (ie, peripheral autonomic failure) than in patients with MSA (ie, central autonomic failure; see Fig  3A) , but there was substantial overlap in the values. Using the DHR/DSBP ratio does not improve diagnostic with Lewy bodies, and pure autonomic failure) had significantly less HR increase than those with central neurogenic OH (ie, multiple system atrophy; analysis of covariance controlling for age p 5 0.023). Although the orthostatic HR changes were more preserved in central autonomic failure, neither of these measurements provided a robust method to discriminate between central and peripheral autonomic failure. (B) Receiver operating characteristic (ROC) curve of the orthostatic HR changes revealing only moderate sensitivity and specificity to distinguish nonneurogenic from neurogenic OH. (C) The DHR/D systolic blood pressure (SBP) ratio was significantly higher in patients with nonneurogenic compared to those with neurogenic OH but did not distinguish among patients with neurogenic OH. (D) ROC curve showing the sensitivity and specificity of the DHR/DSBP ratio to distinguish between nonneurogenic and neurogenic OH, which are considerably better than using the orthostatic HR increase alone (B). BP 5 blood pressure.
accuracy. Nevertheless, differences in the HR rise are of physiological interest, and combined with other markers, 22, 35 might help in the differential diagnosis of patients with neurogenic OH.
Patients with autonomic failure due to disorders that affect postganglionic sympathetic fibers innervating the heart (PAF, PD, and DLB) had the smallest rise in HR during tilt (p 5 0.0002), whereas the largest increases in HR were recorded in patients with MSA in whom postganglionic sympathetic neurons and their axons innervating the heart are mostly spared. 23, 36 Given that parasympathetic modulation of the heart was equally affected in central and peripheral lesions, the data suggest that it is the difference in residual cardiac sympathetic outflow that drives the greater HR rise. There was a weak but significant association between the release of NE upright and the orthostatic HR rise (R 2 5 0.072, p 5 0.0016). This is consistent with the observation that there is a biphasic mode of tachycardia elicited by the upright posture; initially it depends on parasympathetic withdrawal, but sympathetic stimulation is the predominant mechanism when stabilization in the orthostatic position is attained. 7 Other reports have also shown a more preserved HR increase in patients with MSA compared to patients with PD, 37 with chronotropic insufficiency having been described in the latter group. 38, 39 Similarly, we have recently shown that patients with MSA typically have an HR increase of >10 bpm and patients with PD/DLB have an average increase of <9 bpm, whereas those with PAF have the smallest increase of <6 bpm. 22 This supports the hypothesis that the extent of peripheral sympathetic denervation is the main determinant of the ability to increase HR on standing.
Patients with MSA have loss of autonomic neurons in the brainstem and the spinal cord, with relative preservation of postganglionic sympathetic innervation. 21, 40 Using stringent criteria to define PAF in the absence of signs indicating CNS involvement such as REM sleep behavior disorder and anosmia, we were able to select a cohort of patients with truly isolated peripheral autonomic failure. 22, 41 Those with apparent prodromal disease will continue to be followed to ascertain the predictive value of the HR changes and the prognostic implications.
In patients with neurodegenerative autonomic failure as a result of abnormal deposition of the protein asynuclein, preservation of the peripheral sympathetic nerves and less blunted HR responses to tilt were indicative of a worse prognosis (ie, a diagnosis of MSA 22 ). In line with this, the usefulness of the HR rise was recently validated prospectively as an autonomic biomarker in discriminating the future risk of a patient who presents with isolated OH in the prodromal phase, later being diagnosed with MSA or PD/DLB, when other causes of impaired cardiovagal function, including type 2 diabetes mellitus, 42 have been ruled out. 22 Specifically, all patients presenting with neurogenic OH who later developed MSA had an increase in HR of >10 bpm during headup tilt, whereas all those who eventually developed DLB/ PD had a rise of <11 bpm. The cohort here described included 154 patients who were classified as having early, prodromal PD/DLB or prodromal MSA. Most of these patients would have classically been considered as having PAF, but on account of them having subtle motor signs, anosmia, and/or REM behavior disorder, they already had signs of early CNS involvement. Because at the time of writing, it was unclear whether these patients would evolve into PD/ DLB or MSA, we could not ascertain unequivocally whether they had a central or peripheral lesion. We suspect that given that the prodromal cohort is currently older in age and has slower resting HR, and their DHR/ DSBP ratio is significantly lower compared to patients with central autonomic failure (p 5 0.020), the vast majority will eventually be diagnosed with PD or DLB, rather than MSA. This is consistent with our recently reported data on the natural history of PAF, where only 8% of patients with autonomic failure and biomarkers of early CNS involvement phenoconverted to MSA within 4 years. 22 Thus, finding a central autonomic lesion in a patient with autonomic failure has prognostic value. Our study has limitations. Diagnosis was made clinically, and pathological confirmation was lacking. The HR changes were measured in response to tilt (ie, passive standing) and not in response to active standing, which may be more widely used in the clinical setting, although it should be expected to be similar. 43 A blunted HR response to standing has also been described in patients with OH due to diabetic autonomic neuropathy. 42, 44 We specifically excluded patients with diabetes mellitus, however, because of their frequent cardiovascular comorbidities, dehydration, prevalence of antihypertensive medication, and other factors that would make it more difficult to interpret the HR changes. Although we did capture a range of severities of autonomic failure in the cohort, it may also be possible that owing to referral bias, the results are skewed toward more severe cases of autonomic failure, which were referred to specialized autonomic clinics. The number of cases with nonneurogenic OH was smaller, but did allow for nonparametric statistical comparisons. We did not include a comparison group of normal controls, as this would have required provocation to induce BP changes, and would not be directly comparable. Nevertheless, reports in the literature show baroreflex gain in healthy elderly subjects is >2.0 bpm/mmHg, and therefore considerably higher than the ones we here describe in patients with neurogenic OH. 34, 45, 46 Calculating baroreflex gain from the hemodynamic changes in the upright posture may involve inputs from other afferent systems than those involved during the Valsalva maneuver; however, it nevertheless appears to be a robust and simple physiological measure that can be obtained at the bedside without the need for extensive testing. By virtue of MSA having an earlier age at onset, patients with central autonomic failure were younger than those with peripheral autonomic failure owing to Lewy body disorders. Nevertheless, when age was used as a covariant, the difference in the orthostatic HR response remained significant (ANCOVA, p 5 0.023), with patients with MSA having a rise of 111 bpm compared to 1 7 bpm in patients with Lewy body disorders. Adding other clinical features, such as a younger age at onset and early bladder involvement, 22, 47, 48 might help further define phenoconversion to MSA based on the central localization of the lesion responsible for autonomic failure.
In conclusion, a diagnosis of neurogenic OH is best established using the DHR/DSBP ratio. HR increased significantly more in patients with neurogenic OH with central autonomic lesions due to MSA than in those with peripheral autonomic lesions due to Lewy body disorders, but there was considerable overlap. Patients with OH and reduced HR responses to the upright position with a DHR/DSBP ratio < 0.5 bpm/mmHg require additional screening for primary and/or secondary causes of autonomic failure, such as a neurodegenerative synucleinopathy. Early identification of neurogenic OH may reduce delays in treatment and decrease the need for expensive testing, and could provide information to assist in defining prognosis, especially when used in combination with additional discriminatory biomarkers.
